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A B S T R A C T   
Background: Residents of a large area of North-Eastern Italy were exposed for decades to high concentrations of 
perfluoroalkyl and polyfluoroalkyl substances (PFAS) via drinking water. Serum PFAS levels have been consis-
tently associated with elevated serum lipids, but few studies have been conducted among pregnant women, and 
none has stratified analyses by trimester of gestation. Elevated serum lipid levels during pregnancy can have both 
immediate and long-lasting effects on pregnant women and the developing fetus. We evaluated the association 
between perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and perfluoro-hexanesulfonate 
(PFHxS) levels in relation to lipid profiles in highly-exposed pregnant women. 
Methods: A cross-sectional analysis was conducted in 319 pregnant women (age 14–48 years) enrolled in the 
Regional health surveillance program. Non-fasting blood samples were obtained in any trimester of pregnancy 
and analyzed for PFOA, PFOS and PFHxS, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C). 
Low-density lipoprotein cholesterol (LDL-C) was calculated. The associations between ln-transformed PFAS (and 
categorized into quartiles) and lipids were assessed using generalized additive models. Analyses were adjusted 
for potential confounders and stratified according to pregnancy trimester. 
Results: The geometric means of PFOA, PFOS and PFHxS were 14.78 ng/mL, 2.67 ng/mL and 1.89 ng/mL, 
respectively. The plasma levels of TC, HDL-C and LDL-C increased steadily throughout the trimesters. In the 1st 
trimester, PFOS was positively associated with TC and PFHxS with HDL-C. In the 3rd trimester, instead, an 
inverse relationship was seen between PFOA and PFHxS and both TC and LDL-C. 
Conclusions: Results suggest the associations between PFAS concentrations and lipid profiles in pregnant women 
might differ by trimesters of pregnancy. In the first trimester, patterns are similar to those of non-pregnant women, 
while they differ late in pregnancy. Different independent behavior of PFAS and lipid levels throughout the preg-
nancy might explain our observations. These findings support the ubiquitous exposure to PFAS and possible in-
fluence on lipid metabolisms during pregnancy and suggest a careful evaluation of the timing of PFAS measurement, 
when examining effects of PFAS during pregnancy on gestational outcomes related to serum lipids amounts.  
Abbreviations: ALT, Alanine aminotransferase; BMI, Body mass index; CI, Confidence interval; GAM, Generalized additive models; GM, Geometric mean; HDC, 
Highly developed countries; HMPC, High migratory pressure countries; HDL-C, High density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol; 
LOQ, Limit of quantification; LOD, Limit of detection; MET, Metabolic equivalent of task; PFAS, Perfluoroalkyl and polyfluoroalkyl substances; PFHxS, Perfluoro- 
hexanesulfonate; PFOA, Perfluorooctanoic acid; PFOS, Perfluorooctane sulfonate; SD, Standard deviation; TC, Total cholesterol. 
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francesca.dapra@arpa.veneto.it (F. Daprà), aline.fabricio@aulss3.veneto.it (A.S.C. Fabricio), francesca.russo@regione.veneto.it (F. Russo), tony.fletcher@lshtm. 
ac.uk (T. Fletcher), cristina.canova@unipd.it (C. Canova).  
Contents lists available at ScienceDirect 
Ecotoxicology and Environmental Safety 
journal homepage: www.elsevier.com/locate/ecoenv 
https://doi.org/10.1016/j.ecoenv.2020.111805 
Received 14 September 2020; Received in revised form 30 November 2020; Accepted 10 December 2020   
Ecotoxicology and Environmental Safety 209 (2021) 111805
2
1. Introduction 
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) comprise a 
large group of anthropogenic organic chemicals that have been used 
since the late 1940s in a wide variety of commercial products and in-
dustrial applications due to their unique surfactant and repellant prop-
erties (Fujii et al., 2015; Harada et al., 2007). PFAS are persistent 
environmental contaminants, resistant to biodegradation, photooxida-
tion, direct photolysis, and hydrolysis (Organisation for Economic 
Co-operation and Development (OECD), 2018). Sources of exposure to 
PFAS for humans may include food, drinking water, house dust, air, and 
breast milk for infants (Fromme et al., 2010; Haug et al., 2011; Poothong 
et al., 2020). 
Due to the ubiquitous presence of PFAS, persistency in the environ-
ment, tendency for bioaccumulation and biomagnification and a long 
half-life in humans (Bergman et al., 2013), exposure to PFAS will persist 
for many years, thereby making them a potential hazard to humans. 
PFAS have been associated with a variety of adverse health outcomes 
including hepatotoxicity, tumorigenesis, immunotoxicity, and develop-
mental toxicity (Lau et al., 2007). Metabolic effects including changes in 
lipid profiles and possibly obesity, and diabetes, are some of the 
phenotypic alterations from PFAS exposures (ATSDR, 2018; EFSA Panel 
on Contaminants in the Food Chain (CONTAM) et al., 2018). Both in 
epidemiological studies of populations with background levels of 
exposure and highly exposed populations, levels of PFAS (mainly per-
fluorooctanoic acid-PFOA and perfluorooctane sulfonate-PFOS) have 
been associated with elevated plasma total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C), and high-density lipoprotein choles-
terol (HDL-C) (Canova et al., 2020; Fitz-Simon et al., 2013; Frisbee et al., 
2010; Li et al., 2020; Lin et al., 2019; Maisonet et al., 2015; Nelson et al., 
2010; Steenland et al., 2009; Winquist and Steenland, 2014). Few of 
these studies performed gender-specific analyses (Canova et al., 2020; 
Frisbee et al., 2010; Winquist and Steenland, 2014). 
While detectable blood levels of PFAS have been reported in preg-
nant women in several epidemiological studies (Manzano-Salgado et al., 
2015; Mehta et al., 2020; Spratlen et al., 2019; Yang et al., 2019), only 
few studies investigated the association between PFAS concentrations 
and lipid profiles among the pregnant women (Gardener et al., 2021; 
Matilla-Santander et al., 2017; Skuladottir et al., 2015; Starling et al., 
2014; Yang et al., 2020). Each of the five published studies took blood 
samples for PFAS and lipids measurements in a specific trimester of 
pregnancy. All of them found a positive association of one or more of the 
analyzed PFAS with TC. Only two studies (Starling et al., 2014; Yang 
et al., 2020), examined the association with HDL-C and LDL-C. 
None of these studies of pregnant women was focused on highly 
exposed population. Furthermore, none of them analysed the differences 
in the association between PFAS levels and plasma lipid concentration 
across the three trimesters of pregnancy, nor stratified by trimester of 
pregnancy. Stratification by trimester is of great interest, within a study, 
because it has been demonstrated that serum cholesterol concentrations 
increase markedly over the course of pregnancy (Brizzi et al., 1999; 
Piechota and Staszewski, 1992; Wiznitzer et al., 2009), and PFAS levels 
in maternal serum are known to decrease during pregnancy (Fisher 
et al., 2016; Jain, 2013; Javins et al., 2013). 
Exposure of susceptible populations, including pregnant women and 
developing foetuses to PFAS is a concern due to the vulnerability of early 
life stages to toxic effects and that can also influence health outcomes 
later in life (Rager et al., 2020). Epidemiological studies on pregnant 
women have revealed associations between exposure to specific PFAS 
and a variety of health effects, including altered immune and thyroid 
function, lipid and insulin dysregulation, pregnancy-induced hyperten-
sion or pre-eclampsia, adverse reproductive and developmental out-
comes (Fenton et al., 2020). The association of PFAS levels and 
alteration of lipid profiles in pregnant woman might partially explain 
the pathological mechanisms beyond these associations, because altered 
plasma lipids during pregnancy, are associated with a number of adverse 
outcomes, including preeclampsia (Spracklen et al., 2014). 
PFAS have been demonstrated to have strong binding affinity to 
serum proteins (Gao et al., 2019). In particular, PFAS are structurally 
similar to fatty acids, which leads to a strong binding affinity of PFAS to 
liver-fatty acid binding protein (L-FABP) and an accumulation of PFAS 
in the liver. LFABP is also one of the major proteins in serum (Pelsers 
et al., 2003). The binding between L-FABP and PFAS is suggested to 
potentially influence the uptake and transport of fatty acids and might 
further interfere with glycolipid metabolism (Ng and Hungerbühler, 
2014). The structural similarity of PFAS to fatty acids and their binding 
to L-FABP reinforces the hypothesis of possible lipid regulation disrup-
tion by PFAS (Gao et al., 2019). Human serum albumin (HSA) which is 
the main protein in the blood (Jones et al., 2003; Luo et al., 2012) is 
involved in the transport and distribution of endogenous and exogenous 
ligands (Sleep, 2015). Therefore, the PFASs bound to HSA may also be 
transported to target organs that regulate serum lipid levels. A recent 
study (Fan et al., 2020) showed that HSA mediated the interaction be-
tween PFAS mixtures and serum lipid profiles (HDL, LDL and TC). 
Residents in a large area of the Veneto Region (North-Eastern Italy) 
were exposed to high concentrations of PFAS, particularly PFOA, via 
contaminated drinking water from a manufacturing plant active since 
the late 1960s, until autumn 2013 when water treatment plants were 
equipped with granular activated carbon filters (Pitter et al., 2020). In 
2015–16, a study was conducted to compare the serum PFAS levels of 
the exposed population with those of a control population group living 
in neighbouring areas at background exposure (Ingelido et al., 2018). 
Median concentrations of serum PFOA, PFOS and PFHxS were higher in 
exposed subjects than in non-exposed due to this historical exposure. 
The largest difference was observed for PFOA: median value of the 
exposed group was 13.77 ng/g, eight times higher than the median value 
of the non-exposed group (1.64 ng/g). A publicly funded health sur-
veillance program has been established to aid in the prevention, early 
diagnosis, and treatment of chronic disorders possibly associated with 
PFAS exposure (Pitter et al., 2020). 
Thus, the objective of this study was to evaluate the association be-
tween PFOA, PFOS, and perfluoro-hexanesulfonate (PFHxS) levels and 
serum TC, HDL-C, LDL-C in highly exposed pregnant women. In order to 
analyze the differences in the association between PFAS levels and lipid 
concentration throughout the gestational weeks, we stratified the results 
by trimester of gestation. 
2. Material and methods 
2.1. Study population 
The cross-sectional study included 33,273 individuals (17,271 
women, 51.9%) recruited from January 2017 to February 2020 in the 
health surveillance program offered to the community of Veneto Region 
that was exposed to elevated levels of PFAS via drinking water since the 
late 1960s. Only women who were pregnant at the time of enrolment (n 
= 394) are included in the analysis. Participants ranged in age from 14 
to 48. 
The health surveillance program has been described in more detail 
elsewhere (Pitter et al., 2020). Surveillance involved the active calling of 
the eligible population and the free offer of health examinations 
including: i) a questionnaire on socio-demographic characteristics, 
personal health history, diet and lifestyle characteristics, self-reported 
height and weight; ii) measurement of blood pressure; and iii) 
non-fasting blood and urine samples. All participants provided written 
informed consent. 
Out of 394 pregnant women at enrolment, 72 with missing infor-
mation on gestational weeks and three with missing information on the 
selected covariates were excluded from the analysis, leaving 319 preg-
nant women with complete information on covariates and outcomes of 
interest. There was no missing data on exposure or outcome variables 
(eFig. 1). 
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2.2. PFAS exposure 
Serum concentrations of twelve PFAS were measured by high per-
formance liquid chromatography–isotope dilution tandem mass spec-
trometry (HPLC–MS/MS) (Shimadzu UFLC XR 20 Prominence coupled 
to Sciex API 4000). Further details on the analytical method have been 
described elsewhere (Pitter et al., 2020). The limit of detection (LOD) of 
the method was estimated by injecting consecutive dilutions of cali-
bration standards, and was 0.1 ng/mL for all PFAS. The limit of quan-
tification (LOQ) has been chosen to warrant the same methodological 
performances for all analytes in the measuring range, which was 
0.5–500 ng/mL, and it was experimentally estimated at 0.5 ng/mL 
through repeated tests. 
Only three PFAS were quantifiable in at least 50% of samples and 
these were included in the analyses: PFOA (100%), PFOS (98.8%) and 
PFHxS (92.8%). Samples with a concentration below the LOQ were 
assigned a value equal to the LOQ divided by the square root of 2. 
2.3. Outcome assessment 
Plasma lipid parameters (TC, HDL-C, LDL-C) were measured in non- 
fasting plasma samples, analysed in three laboratories (Arzignano, San 
Bonifacio, Legnago). TC and HDL-C were measured by a direct enzy-
matic colorimetric assay using cholesterol esterase and cholesterol oxi-
dase. The measurement of serum lipids was performed in a Cobas 
automated clinical chemistry analyser (Roche Diagnostics GmbH, 
Mannheim, Germany) in two laboratories and in an AU automated 
clinical chemistry analyser (Beckman-Coulter, CA, USA) in the third 
laboratory. LDL-C was calculated by the Friedewald equation when 
triglycerides were less than 400 mg/dL. 
2.4. Covariates 
Socio-demographic, lifestyle characteristics and medical history in-
formation were collected using structured computer-assisted question-
naire directly from participants during an in-person interview at the 
time of enrolment. In order to maximize data quality by minimizing 
errors and missing values, standard data checks and cleaning procedures 
(e.g., range and consistency checks) were performed. 
The following range of potential confounders were considered based 
on prior literature and through the construction of a directed acyclic 
graph (DAG): laboratory in charge of blood sampling, smoking status 
(current smokers, previous smokers, non-smokers), education 
(Elementary/Middle school, High school, University), country of birth 
(Italy plus other Highly Developed Countries - HDC, High Migratory 
Pressure Countries- HMPC), degree of physical activity (Light, Moder-
ate, or Heavy based on metabolic equivalents of task (METs) per hour 
per day), number of previous deliveries (0, 1, 2+), gestational weeks, 
age (years), pre-pregnancy body mass index (BMI (kg/m2) at baseline 
survey), food intake (tertiles of fruit/vegetables, milk/yogurt, cheese, 
meat, sweet/snacks/sweet beverage, eggs, fish, bread/pasta/cereals 
servings per week). Pregnancy trimesters were classified according to 
the reported gestational week: 1st trimester 0–13 weeks, 2nd trimester 
14–26 weeks, and 3rd trimester 27+ weeks. 
2.5. Statistical analysis 
Since the distributions of PFAS were right-skewed, exposures were 
natural log transformed for statistical analyses. Spearman correlation 
coefficients among PFAS concentrations were calculated. The relation-
ship between PFAS, serum lipids and pregnancy trimester was evaluated 
using a Kruskal-Wallis non-parametric test. 
We fitted generalized additive models (GAMs) with thin plate spline 
smooth terms (Duchon, 1977) to determine linearity of exposur-
e–outcome associations for each PFAS. Degree of smoothing was 
selected by generalized cross validation as implemented in the R pack-
age mgcv (Wood and Simon, 2012) . Since the spline analysis showed 
associations compatible with a linear relationship on the natural-log 
transformed PFAS, linear regression coefficient (β) and 95% confi-
dence intervals (CI) were reported. Exposure levels were also treated as 
quartiles, in order to limit the influence of extreme values. 
All analyses were fully adjusted for the established set of covariates. 
Serum PFAS concentrations were also categorized into quartiles for all 
the analyses. All the continuous variables in the models (age, pregnancy 
BMI at baseline survey, gestational weeks) were modelled using thin 
plate spline. All the analyses were also stratified according to pregnancy 
trimester. 
A sensitivity analysis of the dose-response relationship between 
PFOA and TC was performed adjusted by different subsets of covariates, 
to select the best combination of variables. We fitted a model excluding 
the BMI and a model considering the covariate “pregnancy trimester” 
instead of “gestational weeks”. We also investigated the role of liver 
metabolism as a possible confounder in the relationship between PFAS 
levels and serum lipids. In fact, PFOA activates the lipid anabolism 
related genes which are largely expressed in liver and suppressed lipid 
transport gene, potentially causing elevated lipid synthesis and fat de-
posits in liver cells (Wen et al., 2020). Therefore, we fitted a model 
including alanine aminotransferase (ALT) as continuous variable as 
covariate. ALT was chosen because of its correlation with both abdom-
inal fat (Stranges et al., 2004) and with PFAS serum levels (Darrow et al., 
2016; Gallo et al., 2012; Gleason et al., 2015). 
The level of statistical significance was set at 0.05. All statistical 
analyses were performed with STATA/SE version 13.0 and R version 
4.0.2 were used for statistical analyses. 
3. Results 
The population of 319 pregnant women included in the analysis had 
a mean age of 32.7 years (SD = 4.8). 101 of them (31.66%) were in the 
1st trimester of gestation, 88 (27.59%) in the 2nd trimester and 130 
(40.75%) in the 3rd trimester at the time of enrolment in the study. 
Population characteristics are shown in Table 1. 
PFOA was detected at the highest level (GM 14.78 ng/mL), followed 
eFig. 1. Flowchart of the exclusions.  
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by PFOS (GM 2.67 ng/mL) and PFHxS (GM 1.89 ng/mL) (Table 1). PFAS 
concentrations showed high to moderate pairwise correlations, with the 
stronger correlation seen between PFOA and PFHxS (ρ = 0.89). The 
correlations between PFOS with PFOA (ρ = 0.54) and PFHxS (ρ = 0.56) 
were moderate. 
Table 2 depicts the exposure levels of PFAS and lipid levels in study 
population throughout all three trimesters of pregnancy. There was 
some variability between trimesters and weak evidence of a trend but 
only for PFOA. (Table 2). 
The median plasma concentrations for TC, HDL-C and LDL-C were 
197, 68, and 101 mg/dL, respectively (Table 1). The plasma levels of TC, 
HDL-C and LDL-C increased steadily throughout the trimesters (p < 0.01 
for all outcomes) (Table 2). 
The results on GAM models assessing the relationship between each 
PFAS, considered as ln-linear predictors or categorical (quartiles of 
exposure), and cholesterol levels after adjustment for confounding fac-
tors are presented in Table 3. There was generally a positive association 
for HDL in relation to all three PFAS and inverse associations for LDL. 
For cholesterol, only PFOA showed an association, with a decrease of 
− 4.3 mg/dL (95% CI: − 8.3,− 0.2) for each ln-increase of PFOA, and an 
increasing effect across quartiles. Each ln-increase in PFOA was associ-
ated with an increase in HDL-C of 2.0 mg/dL (95% CI: 0.5,3.5), 4.8 mg/ 
dL for PFOS (95% CI: 2.1,7.5), and 2.6 mg/dL (95% CI: 0.7,4.5) for 
PFHxS. Subjects in the highest PFOS quartile had 9.2 mg/dL (95% CI: 
4.7,13.8) higher HDL-C levels than those in the lowest quartile. Slightly 
lower increments were seen for the other PFAS. 
In the other direction, negative associations between PFOA and 
PFHxS and LDL-C were found. A 1-unit increase in ln-PFOA and ln- 
PFHxS was associated with − 6.7 mg/dL, (95% CI: − 10.2,− 3.3) and 
− 8.2 mg/dL (95% CI: − 12.5,− 3.8) decrease in LDL-C, respectively. 
Subjects in the highest PFOA quartile had − 21.2 mg/dL (95% CI: 
− 32.2,− 10.1) lower HDL-C levels than those in the lower quartile. For 
subjects in the highest PFHxS quartile the decrease was − 18.5 mg/dL 
(95% CI: − 29.3,− 7.7) relative to the first quartile. The association be-
tween PFOS and LDL-C was slightly negative but not significant. As a 
sensitivity analysis, adjusting for pregnancy trimesters instead of 
gestational weeks did not modify the effect estimates in models. 
Table 4 shows the relationship of PFAS and cholesterol levels strat-
ified by trimester of gestation. During the 1st trimester, HDL-C tended to 
be associated positively with the clearest association with PFOS 
(8.31 mg/dL per ln-PFOS increase, 95% CI: 1.07,15.55) and PFHxS 
(5.27 mg/dL per ln-PFHxS increase, 95% CI: 0.62,9.92). In the 2nd 
trimester no associations were evident. In the 3rd trimester, rather 
strong inverse relationships were seen for TC and LDL-C and PFOA and 
PFHxS and less clearly for PFOS. Foreach ln-increase in PFOA a drop of 
− 11.02 mg/dL (95% CI: − 18.07,− 3.96) and − 13.92 mg/dL (95% CI: 
− 20.31,− 7.52) for TC and LDL-C, respectively. Similarly, a decrease of 
− 14.27 mg/dL (95% CI: − 23.51,− 5.03) was seen for TC and 
− 17.36 mg/dL (− 25.78,− 8.94) for LDL-C for each ln-increase in 
PFHxS. 
A sensitivity analysis was performed to examine the potential for 
confounding by the time-lag between the interview and the beginning of 
the study. Adjustment for this variable did not materially change the 
observed association between PFAS and TC levels. Additionally, the 
analysis without the adjustment for BMI did not change the results of the 
associations between PFAS and cholesterol levels. Finally, the analysis 
with the results adjusted for ALT are presented in Supplementary Tables 
1 and 2; ALT did not modify the associations between PFAS and 
cholesterol levels observed. 
4. Discussion 
To our knowledge, this is the first study that provides data on the 
associations of PFAS and lipids in a population of highly exposed 
pregnant women, and the first study that stratified the results by 
trimester of pregnancy. 
Overall, in this relatively small population of highly exposed preg-
nant women there was no clear positive association between TC and 
PFOA, PFOS and PFHxS. In contrast to a number of previous studies, the 
pattern even suggested a modest inverse relationship. Consistent with 
previous studies, we found a positive association between HDL-C and all 
three analysed PFAS. Contrary to previous findings conducted in both 
pregnant and non-pregnant women, though, we found a negative asso-
ciation between PFOA and PFHxS and LDL-C. Most importantly, the 
associations between PFAS concentrations and cholesterol profile 
seemed to differ by trimester of pregnancy. In particular, the inverse 
association between PFAS and LDL-C was seen only in the third trimester 
of pregnancy. 
Previous studies which examined the associations between PFAS and 
lipid profiles in pregnant women only included a homogeneous popu-
lation by gestational week, precluding the examination of patterns 
across trimester. Matilla-Santander et al. (2017) considered 2150 
women in the first trimester of pregnancy. The population of 891 women 
included in the study by Starling et al. (2014), was overwhelmingly in 
the 2nd trimester of gestation., The study by Skuladottir et al. (2015), 
examined 854 women in the 30th gestational week, and the study by 
Gardener et al. considered 433 women in the third trimester of preg-
nancy (Gardener et al., 2021). Finally, the study by Yang et al. included 
436 women and analysed PFAS from a blood draw during the first 
trimester of pregnancy, and lipids levels from a blood draw in the late 
term of pregnancy (Yang et al., 2020). The range of gestational weeks of 
our population was from 0 to 41, with 32%, 28% and 41% in the 1st, 2nd 
and 3rd trimester, respectively. 
The association of PFOA with TC was investigated by all- studies, and 
Table 1 
Characteristics of the study population (n = 319).    
TOTAL (n = 319) 
Exposure variables GM Mean (SD) Min-max Median (Q1-Q3) 
PFOA 14.8 26.2 (28.8) 0.5–181 16 (6.7–35.5) 
PFOS 2.7 3.2 (2.0) 0.35–15.8 2.7 (1.9–3.8) 
PFHxS 1.9 2.8 (2.5) 0.35–16 1.9 (1–3.7) 
Outcomes Mean (SD) Min-max Median (Q1-Q3) 
Total Cholesterol 202.7 (52.8) 109–370 197 (163–234) 
HDL Cholesterol 69.8 (15.2) 35–114 68 (59–79) 
LDL Cholesterol 107.5 (38.8) 0–275 101 (82–128) 
Continuous covariates Mean (SD) Min-max Median (Q1-Q3) 
Age 32.7 (4.8) 18–44 33 (29–36) 
Gestation weeks 21.5 (10.8) 0–41 22 (12–31) 
BMI 24.8 (4.3) 16.6–41.5 24.0 (21.6–27.2) 
Categorical covariates Frequency (%) 
Laboratory 
Arzignano 153 (48.0) 
Legnago 78 (24.5) 
San Bonifacio 88 (27.6) 
Number of previous deliveries 
0 164 (51.4) 
1 116 (36.4) 
2 + 39 (12.2) 
Education 
Elementary/Middle school 41 (12.9) 
High school 163 (51.1) 
University 115 (36.1) 
Physical activitya 
Light 271 (85.0) 
Moderate 27 (8.5) 
Heavy 21 (6.6) 
Country of birth 
HDC 279 (87.5) 
HMPC 40 (12.5) 
Smoking habit 
Non-smokers 215 (67.4) 
Current smokers 20 (6.3) 
Previous smokers 84 (26.3)  
a defined based on an algorithm that combined information reported by each 
subject to intensity, duration and frequency of all types of physical activity 
practiced during the week. 
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a positive relationship was found only in two of them Matilla-Santander 
et al. (2017) and Skuladottir et al. (2015). Three out of five studies also 
found a positive association between PFOS and TC (Gardener et al., 
2021; Skuladottir et al., 2015; Starling et al., 2014). These results were 
not confirmed in our study. In particular our results on a negative as-
sociation in the third trimester were opposite to the positive associations 
reported for the third trimester measurements in Skuladottir et al. 
(2015) and Gardener et al. (2021). Only one out of four studies that 
analysed PFHxS association with TC found a positive relationship (Yang 
et al., 2020). 
Starling et al. and Yang et al. investigated the HDL-C and LDL-C as-
sociations with PFAS (Starling et al., 2014; Yang et al., 2020). Similar to 
the results of our study, Starling et al. found that PFOS, PFOA and PFHxS 
(together with all other analysed PFAS) had higher HDL-C levels asso-
ciated with the highest quartile of exposure, compared to the lowest 
quartile. Yang et al., too, found that serum PFHxS was positively asso-
ciated with serum HDL-C levels. As for LDL-C, in Starling et al., the 
beta-coefficient for an ln-unit change in PFOS was elevated, but it was 
not significant and none of the other six PFAS were associated with 
LDL-C. In the paper by Yang et al., although the association of PFOA 
with HDL-C and LDL-C was non-significant, PFOA was negatively asso-
ciated with the LDL/HDL ratio. Whereas, in the present study we found a 
negative association between PFOA and PFHxS and LDL-C. 
The discrepancies in results between our study and other studies may 
be explained in part by higher PFAS concentrations measured in our 
population and a dominant environmental source, with values of PFOA 
6 times or more and PFHxS 3 times higher than concentrations reported 
in previous studies with a background exposure. These differences in 
concentration were not seen for PFOS, though. Therefore, since we 
found the same patterns of association for both PFOA and PFOS and 
cholesterol levels, there might be other factors influencing the results. 
Our results indicated in the 1st trimester a positive association be-
tween PFOS and TC and between PFHxS and HDL-C. Non-pregnant 
women recruited in the Veneto health surveillance plan (age range 
Table 2 
Characteristics of the study population (n = 319), stratified by pregnancy trimester.  








min-max Median (Q1-Q3) Mean 
(SD) 
min-max Median (Q1- 
Q3) 
Exposure variables 
PFOA 29.9 1.5–181 17.7 25.3 0.6–163 15.4 23.99 0.5–144.7 14.5 0.204 
(32.5) (8.9–35.9) (27.8) (4.7–35.5) (26.15) (6.5–34.4)  
PFOS 3. 5 0.8–11.1 2.9 2.7 0.35–8.4 2.5 3.26 0.35–15.8 2.9 0.026 
(2.0)  (2.2–3.9) (1.3)  (1.8–3.5) (2.25)  (1.8–4.2)  
PFHxS 2.9 0.35–16 2.1 2.6 0.35–14.8 1.7 2.7 0.35–14 1.9 0.549 
(2. 7) (1.1–4.1) (2.5) (0.8–3.4) (2.44) (1–3.7)  
Outcomes           
Total Cholesterol 166.2 111–316 164 183.1 109–269 182.5 244.3 127–370 236 0.0001 
(34.0) (139–189) (34.1) (159.5–206.5) (46.2) (213–271)  
HDL Cholesterol 63.2 35–108 62 67.3 39–106 65.5 76.7 44–114 75 0.0001 
(14.0) (54–71) (14.6) (57–75) (13.7) (67–87)  
LDL Cholesterol 88.4 35–184 88 94.3 42–160 94 131.5 0–275 127 0.0001 
(26.3) (70–103) (24.6) (76–115) (42.3) (107–160)  
Age 32.7 19–44 32 32.5 22–43 33 32.9 18–44 34 0.6726 
(4.1) (30–35) (4.8) (29–36) (5.2) (29–37)  
Gestational 
weeks 
8.9 0–13 9 19.5 14–26 19 32.8 27–41 32 – 
(3.0) (7–11) (3.8) (16–23.5) (3.6) (30–36) 
BMI 23.1 16.56–41.5 22.2 24.4 18.96–35.57 23.9 26.4 18.07–40.4 25.5 0.0001 
(4.5) (20.2–24.9) (3.6) (21.4–26.7) (3.9) (23.7–28.7)   
a Kruskal-Wallis test 
Table 3 
Association between PFAS (ln ng/mL) and lipid profile from GAM models (n = 319), adjusted β coefficientsa and 95% Confidence Intervals (CI).  
PFAS Total Cholesterol HDL Cholesterol LDL Cholesterol 
β (CI 95%) β (CI 95%) β (CI 95%) 
PFOA 
per ln-ng/mL ¡4.25 (¡8.26,¡0.23) 2.01 (0.53,3.48) –6.74 (¡10.15,¡3.34) 
1Q (0.5–6.7) 213.37 68.37 122.81 
2Q (7–16) –1.12 (− 13.24,11.0) 4.56 (0.13,9.00) –4.70 (− 15.02,5.62) 
3Q (16.2–35.5) –12.65 (¡(Liew et al., 2014)25.25,¡0.06) 3.74 (− 0.88,8.37) –15.81 (¡26.55,¡5.07) 
4Q (35.6–181) –13.76 (¡26.68,¡0.83) 6.88 (2.14,11.62) –21.17 (¡32.22,¡10.12) 
PFOS 
per ln-ng/mL 3.01 (− 4.51,10.53) 4.84 (2.15,7.54) –2.50 (− 8.99,3.98) 
(0.35–1.9) 199.06 68.67 108.24 
(2–2.7) 4.42 (− 8.21,17.05) 8.60 (4.07,13.14) –2.76 (− 13.73,8.21) 
(2.8–3.8) –1.65 (− 13.80,10.50) 4.81 (0.49,9.14) –5.10 (− 15.63,5.43) 
(3.9–15.8) 9.89 (− 2.82,22.59) 9.20 (4.65,13.76) 0.01 (− 11.04,11.06) 
PFHxS 
per ln-ng/mL –4.91 (− 10.06,0.24) 2.58 (0.69,4.46) –8.17 (¡12.54,¡3.81) 
(0.35–1) 209.83 68.42 119.31 
(1.1–1.9) 1.86 (− 10.30,14.02) 4.34 (− 0.11,8.78) –1.29 (− 11.69,9.11) 
(2–3.7) –4.61 (− 17.07,7.85) 6.63 (2.07,11.19) –11.15 (¡21.71,¡0.60) 
(3.8–16) –11.60 (− 24.36,1.16) 6.13 (1.49,10.77) –18.46 (¡29.27,¡7.66) 
Figures in bold are statistically significant results (p-value < 0.05) 
a adjusted by age, number of previous deliveries, BMI, physical activity, smoking habits, country of birth, education level, laboratory in charge of the analyses of 
serum lipids, gestation weeks and reported fish consumption (in tertiles) 
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20–39 years) showed similar serum cholesterol levels (means 175.7 mg/ 
dL for TC, 64.1 mg/dL for HDL-C and 94.2 mg/dL for LDL-C), and PFAS 
levels (means: 36.89 ng/mL for PFOA, 3.59 ng/mL for PFOS and 
3.23 ng/mL for PFHxS) to that of women in the 1st trimester (Canova 
et al., 2020). Remarkably, non-pregnant women showed a positive 
relationship of PFAS with HDL-Cholesterol that was nonsignificant 
among males, and a lower magnitude of the effect on LDL-C compared to 
men (Canova et al., 2020). Few studies have published gender-specific 
results on lipids and PFAS associations (Canova et al., 2020; Frisbee 
et al., 2010; Winquist and Steenland, 2014), therefore limiting com-
parisons with non-pregnant women. 
However, in the 3rd trimester a strong inverse relationship was seen 
between PFOA and PFHxS and both TC and LDL-C. This unexpected 
pattern, opposite in direction to what would have been expected, could 
potentially be explained by different behavior of PFAS and lipid levels 
among pregnancy trimesters influenced by maternal excretion and dif-
ferential transfer and bioaccumulation of lipids and PFAS in the placenta 
and foetus across gestation. 
In fact, in our study, the concentration of PFOA decreased during 
pregnancy from 17.7 ng/mL in the first trimester, to 14.5 ng/mL in the 
third trimester. The same pattern has been also found in previous studies 
with background exposure (Mamsen et al., 2019; Monroy et al., 2008). 
In a previous study where PFAS serum samples were collected at 24–28 
weeks of gestation and at delivery, authors found that the concentrations 
of PFOS and PFOA were significantly higher at mid-pregnancy 
compared with delivery (median PFOA level of 2.13 ng/mL at 24/28 
weeks and 1.58 ng/mL at delivery) (Monroy et al., 2008). Another study 
examining women in different trimesters of gestation found that the 
maternal serum PFAS concentrations were higher in the first trimester 
than the second and third trimesters, with PFOA levels of 1.51 ng/mL 
and 1.36 ng/mL in the first and third trimester, respectively (Mamsen 
et al., 2019). These changes throughout the gestation could be explained 
by the physiological increase in maternal blood volume, renal clearance 
during pregnancy or transfer of PFAS to the fetus (Loccisano et al., 
Table 4 
Association between PFAS (ln ng/mL) and lipid profile from GAM models (n = 319), adjusted β coefficientsa and 95% Confidence Intervals (CI), stratified by pregnancy 
trimester.   
TOTAL CHOLESTEROL HDL CHOLESTEROL LDL CHOLESTEROL  
Gestation trimesters β (CI 95%) Gestation trimesters β (CI 95%) Gestation trimesters β (CI 95%) 
PFOA 
I Trimester Per ln-ng/mL 7.62 (− 1.33,16.57) Per ln-ng/mL 2.88 (− 1.03,6.8) Per ln-ng/mL 3.45 (− 3.30,10.22) 
1Q (1.5–8.9) 145.44 1Q (1.5–8.9) 56.14 1Q (1.5–8.9) 81.17 
2Q (9.1–17.7) 18.7 (− 4.65,42.07) 2Q (9.1–17.7) 7.49 (− 2.08,17.07) 2Q (9.1–17.7) 8.48 (− 9.91,26.88) 
3Q (18.2–35.9) 7.85 (− 15.63,31.34) 3Q (18.2–35.9) 3.91 (− 5.68,13.52) 3Q (18.2–35.9) 0.49 (− 17.95,18.93) 
4Q (37.2–181) 18.85 (− 5.49,43.2) 4Q (37.2–181) 12.32 (2.36,22.28) 4Q (37.2–181) 5.05 (− 14.07,24.18) 
II Trimester Per ln-ng/mL –0.55 (− 7.20,6.08) Per ln-ng/mL 1.34 (− 1.85,4.54) Per ln-ng/mL –1.8 (− 6.93,3.31) 
1Q (0.6–4.6) 206.28 1Q (0.6–4.6) 55.51 1Q (0.6–4.6) 125.32 
2Q (4.8–14.7) –4.78 (− 25.62,16.05) 2Q (4.8–14.7) 4.61 (− 4.60,13.84) 2Q (4.8–14.7) –10.61 (− 26.9,5.67) 
3Q (16–35.4) –5.67 (− 28.46,17.11) 3Q (16–35.4) 6.03 (− 4.05,16.12) 3Q (16–35.4) –12.53 (− 30.03,4.95) 
4Q (35.6–163) –8.5 (− 31.64,14.62) 4Q (35.6–163) 6.71 (− 3.53,16.95) 4Q (35.6–163) –15.67 (− 33.46,2.12) 
III Trimester Per ln-ng/mL –11.02 (¡18.07,¡3.96) Per ln-ng/mL 1.98 (− 0.15,4.13) Per ln-ng/mL –13.92 (¡20.31,¡7.52) 
1Q (0.5–6.5) 300.17 1Q (0.5–6.5) 76.52 1Q (0.5–6.5) 187.63 
2Q (6.6–14.3) –6.95 (− 30.65,16.74) 2Q (6.6–14.3) 5.93 (− 1.02,12.89) 2Q (6.6–14.3) –8.57 (− 30.11,12.96) 
3Q (14.6–34.4) –29.62 (¡53.12,¡6.13) 3Q (14.6–34.4) 7.24 (0.39,14.09) 3Q (14.6–34.4) –27.79 (¡49.15,¡6.43) 
4Q (35.2–144.7) –40.48 (¡65.15,¡15.81) 4Q (35.2–144.7) 9.53 (2.30,16.75) 4Q (35.2–144.7) –48.6 (¡71.21,¡25.99) 
PFOS 
I Trimester Per ln-ng/mL 15.34 (− 1.08,31.78) Per ln-ng/mL 8.31 (1.07,15.55) Per ln-ng/mL 6.65 (− 5.9,19.2) 
1Q (0.8–2.2) 140.76 1Q (0.8–2.2) 58.68 1Q (0.8–2.2) 69.56 
2Q (2.3–2.9) 2.53 (− 20.66,25.73) 2Q (2.3–2.9) 7.94 (− 1.68,17.57) 2Q (2.3–2.9) –3.5 (− 21.15,14.13) 
3Q (3–3.9) 21.00 (− 3.65,45.65) 3Q (3–3.9) 5.96 (− 4.25,16.18) 3Q (3–3.9) 16.63 (− 2.13,5.36) 
4Q (4.2–11.1) 8.86 (− 14.42,32.14) 4Q (4.2–11.1) 9.39 (− 0.24,19.04) 4Q (4.2–11.1) –0.64 (− 18.33,17.03) 
II Trimester Per ln-ng/mL –2.86 (− 17.86,12.13) Per ln-ng/mL 3.76 (− 3.35,10.87) Per ln-ng/mL –3.51 (− 14.72,7.69) 
1Q (0.35–1.8) 198.26 1Q (0.35–1.8) 52.82 1Q (0.35–1.8) 116.47 
2Q (1.9–2.4) 3.01 (− 20.08,26.1) 2Q (1.9–2.4) 9.71 (− 0.13,19.57) 2Q (1.9–2.4) –4.04 (− 22.23,14.14) 
3Q (2.5–3.4) –1.32 (− 23.86,21.2) 3Q (2.5–3.4) 1.23 (− 8.37,10.84) 3Q (2.5–3.4) 0.59 (− 17.22,18.4) 
4Q (3.5–8.4) 3.06 (− 20.52,26.66) 4Q (3.5–8.4) 10.07 (0.01,20.13) 4Q (3.5–8.4) –4.56 (− 23.81,14.68) 
III Trimester Per ln-ng/mL –4.51 (− 18.13,9.09) Per ln-ng/mL 4.25 (0.26,8.24) Per ln-ng/mL –10.05 (− 22.71,2.61) 
1Q (0.35–1.8) 284.64 1Q (0.35–1.8) 76.62 1Q (0.35–1.8) 174.85 
2Q (1.9–2.8) –31.64 (¡56.9,¡6.38) 2Q (1.9–2.8) 7.57 (0.31,14.83) 2Q (1.9–2.8) –32.16 (¡55.9,¡8.42) 
3Q (2.9–4.2) –28.75 (¡52.59,¡4.9) 3Q (2.9–4.2) 10.70 (3.85,17.56) 3Q (2.9–4.2) –31.94 (¡54.39,¡9.5) 
4Q (4.3–15.8) –3.18 (− 28.23,21.86) 4Q (4.3–15.8) 6.11 (− 1.08,13.31) 4Q (4.3–15.8) –10.74 (− 34.3,12.8) 
PFHxS 
I Trimester Per ln-ng/mL 10.08 (− 0.58,20.75) Per ln-ng/mL 5.27 (0.62,9.92) Per ln-ng/mL 3.43 (− 4.68,11.56) 
1Q (0.35–1.1) 142.55 1Q (0.35–1.1) 54.06 1Q (0.35–1.1) 78.5 
2Q (1.2–2.1) 16.31 (− 6.91,39.54) 2Q (1.2–2.1) 4.83 (− 4.56,14.23) 2Q (1.2–2.1) 11.49 (− 6.53,29.53) 
3Q (2.2–4.1) 5.66 (− 17.79,29.11) 3Q (2.2–4.1) 3.79 (− 5.73,13.31) 3Q (2.2–4.1) -0.01 (− 18.27,18.24) 
4Q (4.2–16) 16.22 (− 8.15,40.6) 4Q (4.2–16) 13.08 (3.18,22.98) 4Q (4.2–16) 2.28 (− 16.68,21.25) 
II Trimester Per ln-ng/mL -1.13 (− 10.18,7.92) Per ln-ng/mL 0.4 (− 3.94,4.76) Per ln-ng/mL -1.1 (− 8.02,5.82) 
1Q (0.35–0.8) 207.65 1Q (0.35–0.8) 57.3 1Q (0.35–0.8) 125.9 
2Q (0.9–1.7) -8.05 (− 30.21,14.09) 2Q (0.9–1.7) 7.47 (− 2.31,17.26) 2Q (0.9–1.7) -12.04 (− 29.16,5.08) 
3Q (1.9–3.3) -6.48 (− 30.93,17.97) 3Q (1.9–3.3) 6.46 (− 4.34,17.27) 3Q (1.9–3.3) -9.52 (− 28.33,9.29) 
4Q (3.4–14.8) -8.35 (− 32.13,15.42) 4Q (3.4–14.8) 3.37 (− 7.13,13.88) 4Q (3.4–14.8) -12.69 (− 31.19,5.8) 
III Trimester Per ln-ng/mL -14.27 (¡23.51,¡5.03) Per ln-ng/mL 2.88 (0.05,5.71) Per ln-ng/mL -17.36 (¡25.78,¡8.94) 
1Q (0.35–1) 286.97 1Q (0.35–1) 79.48 1Q (0.35–1) 173.07 
2Q (1.1–1.9) -10.86 (− 36.43,14.7) 2Q (1.1–1.9) 3.97 (− 3.38,11.34) 2Q (1.1–1.9) -8.82 (− 32.43,14.78) 
3Q (2–3.7) -26.27 (¡50.3,¡2.24) 3Q (2–3.7) 8.67 (1.74,15.6) 3Q (2–3.7) -26.18 (¡48.15,¡4.21) 
4Q (3.8–14) -30.68 (¡55.44,¡5.92) 4Q (3.8–14) 6.99 (− 0.15,14.14) 4Q (3.8–14) -35.88 (¡58.52,¡13.24)  
a adjusted by age, number of previous deliveries, BMI, physical activity, smoking habits, country of birth, education level, laboratory in charge of the analyses of 
serum lipids, gestation weeks and reported fish consumption (in tertiles) 
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2013). The study by Monroy et al. found that PFOA and PFOS were also 
detectable, to a lesser extent, in 100% of samples of umbilical cord, 
concluding that PFOA and PFOS can cross the fetal–placental barrier 
during pregnancy resulting in exposure of the developing fetus (Monroy 
et al., 2008). Furthermore, there was a high correlation between 
maternal serum levels and cord blood at delivery. The study by Mamsen 
et al. analysed presence of PFAS in the placenta and fetal tissues and 
found that fetal age was positively associated with the placenta: 
maternal serum ratios of PFOS, PFOA and PFNA, suggesting that these 
substances accumulate in the placenta across gestation and give rise to 
an increased fetal burden (Mamsen et al., 2019). Prenatal exposure to 
PFOS and PFOA has been associated with low birth weight in humans 
(Fei et al., 2007; Lauritzen et al., 2017; Maisonet et al., 2012), although 
reports were inconsistent (Bach et al., 2015). In rodents, high exposure 
of PFOS and PFOA during pregnancy have been associated with reduced 
postnatal survival, lower birth weight, decreased growth of the pups, 
disturbed lactation (Lau et al., 2006, 2004, 2003; Olsen et al., 2009), and 
disrupted thyroid function (Yu et al., 2009). Also, concentrations of 
PFOS and PFOA in cord blood have been associated with an increased 
risk of congenital cerebral palsy in Danish boys (Liew et al., 2014) and 
PFOA in cord plasma has been suggested to increase the thyroxine 
hormone level in newborn girls (de Cock et al., 2014). It has been also 
demonstrated that lipid parameters are elevated in pregnancy. TC and 
LDL-C start to rise significantly in the second and third trimesters (Brizzi 
et al., 1999; Piechota and Staszewski, 1992), while for HDL-C the trend 
is less linear, with a maximum increase in the 2nd trimester and a 
decrease hereafter (Piechota and Staszewski, 1992). Also, some studies 
support the hypothesis that maternal cholesterol can cross the placenta, 
even if the fetus can produce endogenous cholesterol and has some 
ability to regulate its own cholesterol levels (Woollett, 2005). In fact, the 
correlation between maternal and fetal cholesterol seems to be strong up 
to the 28th week of gestation only, and not correlated at birth (Napoli 
et al., 1997). A recent study by Spratlen et al. on the correlation between 
PFAS and lipids in cord blood found that there were significant associ-
ations between higher levels of PFOS, PFOA, and PFHxS with higher 
total cord lipids (Spratlen et al., 2020). This association may also explain 
some health outcomes in the newborns. Higher cord lipid levels have 
been consistently reported in low birth weight and 
small-for-gestational-age newborns, both established risk factors for 
cardiovascular disease in adulthood (Crispi et al., 2018; Smith et al., 
2016). 
To explain our observations, it is also possible to hypothesize a role 
for placental transfer of PFAS. It has been demonstrated that PFAS may 
bind to albumin (Fan et al., 2020) and, although albumin levels are 
positively associated with PFASs also in pregnant women (Jiang et al., 
2014), passive diffusion of PFAS is more likely involved for the placental 
transport of free fraction, as albumin can hardly transfer across the 
placental barrier (Lambot et al., 2006). During pregnancy, and partic-
ularly during the 3rd trimester, albumin concentration is reduced in the 
mother circulation due to plasma volume expansion, increased extra-
vascular volume and increase in urinary excretion (Higby et al., 1994; 
Kristensen et al., 2007). This process may contribute to an altered 
equilibrium between free and albumin-bound fraction of PFAS in favor 
of an increase in the free fraction, readily available for placental trans-
fer. Fan et al. (2020) demonstrated that albumin mediates the toxic ef-
fect of PFAS exposure on the levels of serum lipids. Therefore, the 
decrease in circulating levels of albumin-bound PFAS may be associated 
to a reduction of PFAS-induced lipid changes in pregnant women. One 
can therefore hypothesize that the lower availability of albumin-bound 
PFAS in maternal serum caused by placental transfer of free fraction of 
PFAS can, in some way, disrupts the positive association of PFAS with 
lipids observed in early phases of pregnancy. It should be noted that 
these explanations are speculative and that this and other mechanisms 
should be explored. Moreover, whatever the relative contribution of the 
proposed mechanism to the inversion of associations found at the 3rd 
semester, it is probably overcome by the high increase in lipids levels 
observed in maternal serum in this period. 
Given all these differences, in both lipids and PFAS during preg-
nancy, it is plausible that whatever causal or non-causal mechanism 
leads to observed associations between PFAS and lipids, the associations 
differ in pregnant women compared to non-pregnant women, and 
throughout the trimesters of pregnancy. Also, given the independent 
effect of pregnancy on PFAS and lipids, isolating the direct effect of PFAS 
on lipids over the course of pregnancy is a complex challenge as re-
flected in our findings. All of these aspects can lead to exposure 
misclassification when PFAS levels are measured at different pregnancy 
time-points. 
The strengths of our study are the adjustment for a large set of 
possible confounders and the robust statistical methods. The limitations 
are the small sample size, and the cross-sectional design which does not 
allow causal interpretation of the finding. Another limitation is that we 
did not retrieve any data about previous breastfeeding of our subjects. 
Breastfeeding is one of the major determinants of PFAS excretion and 
serum levels of adult women (Herrick et al., 2017; Liu et al., 2011). 
Nevertheless, we adjusted our models for parity that could reflect, 
although not precisely, number of previous breastfed children. We also 
did not retrieve information on the pre-pregnancy BMI and changes in 
BMI (weight gain) in different gestational weeks during the pregnancy. 
To avoid possible bias related to the changes in pregnancy BMI, a 
sensitivity analysis was conducted excluding information on the preg-
nancy BMI at baseline survey as covariate and found a similar associa-
tion between PFOA and TC. 
Another possible limitation is that PFAS have been suggested to 
impair fertility (Bach et al., 2016) and to increase risk of miscarriages 
(Darrow et al., 2014). All these mechanisms could result in a selection 
bias, for which those most highly exposed might possibly have a lower 
chance of being enrolled in a pregnancy cohort. 
In this study, serum lipids were analysed in 3 different labs, using 
different analytical platforms. Although not identical, these methods 
have been shown to be correlated (Kim et al., 2014). With adjusting for 
laboratory in charge of blood sampling, we accounted for any effects of 
the different analytical analyses. Finally, no adjustment was possible for 
fasting because the information of time since the last meal was lacking. 
Fasting status may affect serum lipid levels, however, circulating levels 
of plasma lipids are modestly influenced by food consumption. Studies 
comparing fasting with non-fasting lipid levels stated that there was no 
relevant change in TC, LDL-C, and HDL-C. (Dipankar and Pawar, 2019; 
Langsted et al., 2014; Langsted and Nordestgaard, 2019; Mora et al., 
2008). Therefore, we believe it’s unlikely that the variability of fasting 
time significantly affected serum cholesterol levels. 
5. Conclusion 
Altogether, despite the small sample size, this study makes an 
innovative contribution, that should be confirmed by further studies 
with a bigger sample size. For the first time it has been found that the 
associations between PFAS and cholesterol profiles change throughout 
all three trimesters of pregnancy. While in the first trimester the patterns 
of associations between PFAS and LDL-C were similar to those of non- 
pregnant women, the associations were inverted during the third 
trimester of gestation, with a negative relationship. Prospective studies 
that evaluated effects of prenatal exposure to PFAS have utilized 
different pregnancy time-points, varying from the 1st trimester to de-
livery (Liew et al., 2018). These results, if confirmed, indicate that the 
timing of PFAS measurement during pregnancy should be carefully 
evaluated, when planning longitudinal studies examining effects of 
PFAS during pregnancy on gestational outcomes or children related to 
serum lipids amounts. 
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Zolin, R., Bettega, A.M., Stopazzolo, G., Vittorii, S., Zambelli, L., Martuzzi, M., 
Mantoan, D., Russo, F., 2020. Serum Levels of Perfluoroalkyl Substances (PFAS) in 
Adolescents and Young Adults Exposed to Contaminated Drinking Water in the 
Veneto Region, Italy: A Cross-Sectional Study Based on a Health Surveillance 
Program. In: Environ. Health Perspect., 128 https://doi.org/10.1289/EHP5337. 
Poothong, S., Papadopoulou, E., Padilla-Sánchez, J.A., Thomsen, C., Haug, L.S., 2020. 
Multiple pathways of human exposure to poly- and perfluoroalkyl substances 
(PFASs): from external exposure to human blood. Environ. Int. 134, 105244 https:// 
doi.org/10.1016/j.envint.2019.105244. 
Rager, J.E., Bangma, J., Carberry, C., Chao, A., Grossman, J., Lu, K., Manuck, T.A., 
Sobus, J.R., Szilagyi, J., Fry, R.C., 2020. Review of the environmental prenatal 
exposome and its relationship to maternal and fetal health. Reprod. Toxicol. 98, 
1–12. https://doi.org/10.1016/j.reprotox.2020.02.004. 
Skuladottir, M., Ramel, A., Rytter, D., Haug, L.S., Sabaredzovic, A., Bech, B.H., 
Henriksen, T.B., Olsen, S.F., Halldorsson, T.I., 2015. Examining confounding by diet 
in the association between perfluoroalkyl acids and serum cholesterol in pregnancy. 
Environ. Res. 143, 33–38. https://doi.org/10.1016/j.envres.2015.09.001. 
Sleep, D., 2015. Albumin and its application in drug delivery. Expert Opin. Drug Deliv. 
12, 793–812. https://doi.org/10.1517/17425247.2015.993313. 
Smith, C.J., Ryckman, K.K., Barnabei, V.M., Howard, B.V., Isasi, C.R., Sarto, G.E., Tom, S. 
E., Van Horn, L.V., Wallace, R.B., Robinson, J.G., 2016. The impact of birth weight 
on cardiovascular disease risk in the Women’s Health Initiative. Nutr. Metab. 
Cardiovasc. Dis. 26, 239–245. https://doi.org/10.1016/j.numecd.2015.10.015. 
Spracklen, C.N., Smith, C.J., Saftlas, A.F., Robinson, J.G., Ryckman, K.K., 2014. Maternal 
hyperlipidemia and the risk of preeclampsia: a meta-analysis. Am. J. Epidemiol. 180, 
346–358. https://doi.org/10.1093/aje/kwu145. 
Spratlen, M.J., Perera, F.P., Lederman, S.A., Robinson, M., Kannan, K., Trasande, L., 
Herbstman, J., 2019. Cord blood perfluoroalkyl substances in mothers exposed to the 
World Trade Center disaster during pregnancy. Environ. Pollut. 246, 482–490. 
https://doi.org/10.1016/j.envpol.2018.12.018. 
T. Dalla Zuanna et al.                                                                                                                                                                                                                         
Ecotoxicology and Environmental Safety 209 (2021) 111805
10
Spratlen, M.J., Perera, F.P., Lederman, S.A., Robinson, M., Kannan, K., Herbstman, J., 
Trasande, L., 2020. The association between perfluoroalkyl substances and lipids in 
cord blood. J. Clin. Endocrinol. Metab. 105, 43–54. https://doi.org/10.1210/ 
clinem/dgz024. 
Starling, A.P., Engel, S.M., Whitworth, K.W., Richardson, D.B., Stuebe, A.M., Daniels, J. 
L., Haug, L.S., Eggesbø, M., Becher, G., Sabaredzovic, A., Thomsen, C., Wilson, R.E., 
Travlos, G.S., Hoppin, J.A., Baird, D.D., Longnecker, M.P., 2014. Perfluoroalkyl 
substances and lipid concentrations in plasma during pregnancy among women in 
the Norwegian Mother and Child Cohort Study. Environ. Int. 62, 104–112. https:// 
doi.org/10.1016/j.envint.2013.10.004. 
Steenland, K., Tinker, S., Frisbee, S., Ducatman, A., Vaccarino, V., 2009. Association of 
perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among 
adults living near a chemical plant. Am. J. Epidemiol. 170, 1268–1278. https://doi. 
org/10.1093/aje/kwp279. 
Stranges, S., Dorn, J.M., Muti, P., Freudenheim, J.L., Farinaro, E., Russell, M., 
Nochajski, T.H., Trevisan, M., 2004. Body fat distribution, relative weight, and liver 
enzyme levels: a population-based study. Hepatology 39, 754–763. https://doi.org/ 
10.1002/hep.20149. 
Wen, Y., Mirji, N., Irudayaraj, J., 2020. Epigenetic toxicity of PFOA and GenX in HepG2 
cells and their role in lipid metabolism. Toxicol. Vitr. 65, 104797 https://doi.org/ 
10.1016/j.tiv.2020.104797. 
Winquist, A., Steenland, K., 2014. Modeled PFOA exposure and coronary artery disease, 
hypertension, and high cholesterol in community and worker cohorts. Environ. 
Health Perspect. 122, 1299–1305. https://doi.org/10.1289/ehp.1307943. 
Wiznitzer, A., Mayer, A., Novack, V., Sheiner, E., Gilutz, H., Malhotra, A., Novack, L., 
2009. Association of lipid levels during gestation with preeclampsia and gestational 
diabetes mellitus: a population-based study. Am. J. Obstet. Gynecol. 201, 482. 
e1–482.e8. https://doi.org/10.1016/j.ajog.2009.05.032. 
Wood, Simon, 2012 Mgcv: Mixed GAM Computation Vehicle with GCV/AIC/REML 
Smoothness Estimation. https://researchportal.bath.ac.uk/en/publications/mgcv- 
mixed-gam-computation-vehicle-with-gcvaicreml-smoothness-est. 
Woollett, L.A., 2005. Maternal cholesterol in fetal development: transport of cholesterol 
from the maternal to the fetal circulation. Am. J. Clin. Nutr. 82, 1155–1161. https:// 
doi.org/10.1093/ajcn/82.6.1155. 
Yang, J., Wang, H., Du, H., Xu, L., Liu, S., Yi, J., Qian, X., Chen, Y., Jiang, Q., He, G., 
2019. Factors associated with exposure of pregnant women to perfluoroalkyl acids in 
North China and health risk assessment. Sci. Total Environ. 655, 356–362. https:// 
doi.org/10.1016/j.scitotenv.2018.11.042. 
Yang, J., Wang, H., Du, H., Fang, H., Han, M., Xu, L., Liu, S., Yi, J., Chen, Y., Jiang, Q., 
He, G., 2020. Serum perfluoroalkyl substances in relation to lipid metabolism in 
Chinese pregnant women. Chemosphere, 128566. https://doi.org/10.1016/j. 
chemosphere.2020.128566. 
Yu, W.-G., Liu, W., Jin, Y.-H., Liu, X.-H., Wang, F.-Q., Liu, L., Nakayama, S.F., 2009. 
Prenatal and postnatal impact of perfluorooctane sulfonate (PFOS) on rat 
development: a cross-foster study on chemical burden and thyroid hormone system. 
Environ. Sci. Technol. 43, 8416–8422. https://doi.org/10.1021/es901602d. 
T. Dalla Zuanna et al.                                                                                                                                                                                                                         
